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Amebiasis causes approximately 70,000 deaths annually and is the third cause of
death due to parasites worldwide. It is treated primarily with metronidazole, which has
adverse side effects, is mutagenic and carcinogenic, and emergence of resistance
is an increasing concern. Unfortunately, better therapeutic alternatives are lacking.
Re-purposing of older FDA approved drugs is advantageous to drug discovery since
safety and pharmacokinetic effects in humans are already known. In high throughput
screening studies, we recently demonstrated that auranofin, a gold containing compound
originally approved to treat rheumatoid arthritis, has activity against trophozoites of
E. histolytica, the causative agent of amebiasis. Auranofin’s anti-parasitic activity is
attributed to its monovalent gold molecule that readily inhibits E. histolytica thioredoxin
reductase. This anti-oxidant enzyme is the only thiol-dependent flavo-reductase present
in E. histolytica. Auranofin has also shown promising activity against other protozoans
of significant public health importance. Altogether, this evidence suggests that auranofin
has the potential to become a broad spectrum alternative therapeutic agent for diseases
with a large global burden.
Keywords: amebiasis, thioredoxin reductase, auranofin, Entamoeba histolytica, protozoan, diarrhea
Introduction
The three major causes of protozoal diarrhea worldwide are E. histolytica, G. lamblia, and
Cryptosporidium sp., which cause significant morbidity and mortality in developing and developed
countries (Fletcher et al., 2012). In fact, it is estimated that E. histolytica infects approximately
500 million people worldwide, resulting in 50 million cases of invasive disease and about
70,000 deaths annually (Debnath et al., 2012). Meanwhile, G. lamblia infection prevalence is
estimated at 280 million cases annually1 while Cryptosporidium sp. accounts for about 20%
and up to 9% of diarrheal episodes in children from developing (Simango and Mutikani,
2004; Cama et al., 2008) and developed2 countries respectively. Although Cryptosporidium sp.
infection can be self-limited in immunocompetent people, but it is chronic and debilitating in
immunosuppressed and malnourished individuals (Cabada andWhite, 2010). Because of their link
with poverty and association with poor cognitive function in early childhood (Berkman et al., 2002),
Giardia and Cryptosporidium were included in the WHO Neglected Diseases Initiative in 2004
1http://www.cdc.gov/parasites/giardia/epi.html. July 13, 2012
2http://www.cdc.gov/mmwr/preview/mmwrhtml/ss6105a1.htm
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(Savioli et al., 2006). Also, the National Institutes of Health (NIH)
has listed G. lamblia, C. parvum, and E. histolytica as category
B priority biodefense pathogens because of their low infectious
dose and potential for dissemination through compromised food
and water supplies in the United States3.
Despite their global burden in public health, there are no
vaccines or prophylactic medications to prevent amebiasis,
giardiasis or cryptosporidiosis. Furthermore, first-line treatment
for invasive amebiasis and giardiasis is metronidazole since
1966 (Powell et al., 1967) and 1963 (Lionetto et al., 1963)
respectively. Metronidazole has been shown to be both
mutagenic in a microbiological system and carcinogenic to
rodents and frequently causes gastrointestinal side effects. In
vitro, E. histolytica trophozoites can adapt to therapeutically
relevant levels of metronidazole (Wassmann et al., 1999).
Treatment failures in giardiasis occur in up to 20% of cases
(Upcroft and Upcroft, 2001). Clinical resistance of G. lamblia
to metronidazole has been documented along with cross
resistance to the newer drugs, tinidazole and nitazoxanide,
making drug resistance an increasing concern (Tejman-Yarden
et al., 2013). Nitazoxanide, the only FDA-approved drug for
the treatment of cryptosporidiosis, is effective in the treatment
of immunocompetent patients but only partially effective
for immunosuppressed patients. Therefore, it is critical to
develop more effective drugs to treat amebiasis, giardiasis and
cryptosporidiosis.
Reprofiling of FDA approved drugs is an advantageous
approach to drug discovery since safety and pharmacokinetic
effects in humans have already been confirmed clinically. These
efforts led to the discovery that auranofin, a gold containing
compound that is FDA approved for the treatment of rheumatoid
arthritis, has anti-parasitic activity (Angelucci et al., 2009) Its
anti-parasitic activity, likely stems from the gold molecule that
readily dissociates and inhibits thiol- dependent flavoreductases
(Saccoccia et al., 2012) such as thioredoxin-thioredoxin reductase
and glutathione-glutathione reductase. These latter enzymes are
the twomain detoxifying systems that are independent of reactive
oxygen species (ROS). These antioxidant systems are present in
all protozoan parasites which are constantly exposed to ROS from
their own metabolism and those from the host (Hirt et al., 2002).
Thioredoxin Reductase and its Diversity among
Protozoan Parasites
Like all eukaryotes, protozoan parasites’ defense mechanisms
include anti-oxidant systems to handle ROS challenges. Among
these anti-oxidant systems, free radicals and radical-free systems
are pivotal to maintain the oxidation/reduction homeostasis and
prevent oxidative stress.
Radical-free systems, that include thiol-oxidoreductases, are
essential and abundant enzymatic systems that account for 0.5–
1% of the cell proteome (Fomenko and Gladyshev, 2012). Many
of these thiol-oxidoreductases form protein complexes where
each thiol oxidoreductase frequently contains cysteine (Cys)
as their conserved catalytic residue (Fomenko and Gladyshev,
2012). Thioredoxin-thioredoxin reductase (Trx/TrxR) and
3http://www.niaid.nih.gov/topics/BiodefenseRelated/Biodefense/Pages/CatA.aspx
glutathione-glutathione reductase (GSH/GR) are the two main
detoxifying systems independent of ROS.
The Trx/TrxR system has drawn significant attention due
to its broad substrate specificity, allowing it to play important
roles in regulating DNA synthesis, gene transcription, cell
growth and apoptosis (Nozaki et al., 1999; Becker et al.,
2000). Thioredoxin reductases (TrxRs) are enzymes that belong
to the flavoprotein family of pyridine nucleotide-disulphide
oxidoreductases (Mustacich and Powis, 2000). These enzymes
are homodimeric proteins where each monomer contains a
FAD domain, a NADPH binding domain, and an active site
containing a redox active disulfide (Mustacich and Powis, 2000).
Cysteine is present in the catalytic redox active center, which
is highly conserved in thiol-reductases. The majority of thiol-
oxidoreductases have a single catalytic Cys, but some of these
enzymes are composed of two or more thiol-oxidoreductase
domains, each having the catalytic redox Cys (Fomenko and
Gladyshev, 2012).
Two main types of TrxRs (McMillan et al., 2009) are
recognized:
• High molecular weight (H-TrxR) enzymes that contain a
redox active center (motif CXXXXC) in the FAD binding
domain. H-TrxR is closely related to glutathione reductase
(GR), trypanothione reductase (TryR), mercuric reductase
(MerR) and lipoamide dehydrogenase (LipD) (Nozaki et al.,
1999). There are two varieties of H-TrxR: (a) one that
contains a selenocysteine at the penultimate position in the
C-terminal interface domain: the mammalian form; (b) one
where selenocysteine have been replaced by cysteine in the
interface domain: the apicomplexan parasite form.
• Low molecular weight (L-TrxR) enzymes that contain a redox
active disulfide (motif CXXC) in the NADPH domain. L-
TrxRs are related to alkyl hydroperoxide reductase F52A
(AhpF). It is present in bacteria, fungi, plants and some
protozoan parasites including Trichomonas vaginalis (Nozaki
et al., 1999; Williams et al., 2000; Coombs et al., 2004) and
Entamoeba histolytica (Arias et al., 2007).
Despite only 20% primary sequence identity between H-TrxR
and L-TrxR (Nozaki et al., 1999), they appear to have evolved
from a common ancestor but developed independently. L-TrxR
and H-TrxR are mutually exclusive, suggesting that they do not
act synergistically (Nozaki et al., 1999).
Electrons are transferred from NADPH via FAD to the
active-site disulphide of TrxR, which then reduces the substrate
(thioredoxin). H-TrxR has 3 redox active centers, whereas the
L-TrxR have 2 redox centers and the transfer of reducing
equivalents requires a conformational change, in contrast to
H-TrxR (Williams et al., 2000).
Trx/TrxR systems vary according to parasites subgroups.
Among aerotolerant protozoans, the absence of GSH/GR makes
Trx/TrxR a main member of their antioxidant systems. In fact, E.
histolytica, T. vaginalis and G. lamblia possess a full thioredoxin
system, consisting of thioredoxin (Trx), Trx peroxidase and a L-
TrxR (Hughes et al., 2003; Coombs et al., 2004; Arias et al., 2007;
Leitsch et al., 2009). In the Apicomplexan group, Plasmodium
possesses both GSH/GR and Trx/TrxR redox systems. Its
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complete thioredoxin system comprises thioredoxin reductase
(TrxR), different thioredoxins, thioredoxin-like proteins, and
thioredoxin-dependent peroxidases (TPx) (Kawazu et al., 2001;
Nickel et al., 2006; Kehr et al., 2010).
Genome sequencing of T. brucei (Berriman et al., 2005),
T. cruzi (El-Sayed et al., 2005), and L. major (Ivens et al.,
2005) revealed that trypanosomatids lack genes for GSH/GR
and Trx/TrxR. While in most eukaryotic organisms these latter
systems maintain the intracellular thiol redox homeostasis,
trypanosomatids depend exclusively on trypanothione [N1,N8-
bis(glutathionyl)spermidine; T(SH)2] (Fairlamb et al., 1985;
Fairlamb and Cerami, 1992) and trypanothione reductase (TryR)
to keep dithiols in a reduced form (Fairlamb and Cerami, 1992;
Krauth-Siegel and Comini, 2008). TryR is the only enzyme that
connects the NADPH- and the thiol-based redox systems in
these parasites, and it is related to H-TrxR. As such, it shares
many physical and chemical properties with GR. TryR has been
biochemically characterized in T. cruzi (Krauth-Siegel et al.,
1987), Leishmania (Cunningham and Fairlamb, 1995), and T.
brucei (Sullivan et al., 1989; Jones et al., 2010).
Entamoeba histolytica Thioredoxin Reductase
E. histolytica trophozoites are considered aerotolerant organisms.
They can survive in an anaerobic environment such as that of
the human gut. During tissue invasion, they are exposed to high
levels of ROS. Earlier studies showed that it can tolerate up to
5% oxygen in the gas phase (Bruchhaus et al., 1997; Choi et al.,
2005; Loftus et al., 2005). Hence, the parasite must have means to
minimize damage caused by ROS produced by the host immune
system. In contrast to most organisms, E. histolytica lacks both
glutathione reductase activity and glutathione synthetic enzymes;
therefore, it relies on TrxR to prevent, regulate and repair the
damage caused by oxidative stress.
The E. histolytica genome has a single TrxR-encoding gene
(EHI_155440) (EhTrxR). EhTrxR belongs to the low molecular
weight TrxR family (L-TrxR). It is 964 bp in length, lacks
introns and encodes a 314-amino-acid protein with a molecular
mass of 33.7 kDa and a pI of 6.34. EhTrxR size and domain
topology resembles E. coli TrxR. Both proteins have an active
site dithiol/disulfide center (Cys-Ala-Thr-Cys for EcTrxR, Cys-
Ala-Ile-Cys for EhTrxR). In EhTrxR, the Cys residues in the
catalytic center correspond to Cys 140 and Cys 143. Sequence
homology to other TrxRs is 21% identity to E. coli TrxR (L-
TrxR), Trichomonas vaginalis (23%), Trypanosoma cruzi (27%),
and Homo sapiens (36%) (Arias et al., 2007).
The catalytic mechanism of L-TrxR has been extensively
characterized in E. coli. Spatially, the NADPH and FAD domains
of E. coli ThrxR do not make close contact with the isoalloxazine
ring of FAD. Its NADPH domain rotates 66◦ while the FAD
domain remains fixed. Then, the bound NADPH moves into
close contact with the FAD isoallaxazine ring that allows electron
transfer to FAD and the active-site disulphide (Waksman et al.,
1994).
EhTrxR demonstrates an unusually high level of NADPH
oxidase activity, which is protective against molecular oxygen
required for the survival of these aerotolerant, anaerobic
organisms (Bruchhaus et al., 1998). EhTrxR exhibited NADPH
oxidase activity with hyperbolic saturation kinetics for NADPH,
and its estimated Km andVmax values are 3.6µMand 0.37 U/mg
respectively (Arias et al., 2007). As described by Arias et al. (2007)
EhTrxR is considered a true reductase of thioredoxin in that it
is not able to transfer reducing equivalents directly to Ehp29
(peroxiredoxin). On the other hand, high intracellular levels
of cysteine compensate for the lack of glutathione preventing
auto-oxidation in highly reducing environments (Nozaki et al.,
1999). Interestingly, despite the fact that neither thioredoxin nor
thioredoxin reductase configurations include a transmembrane
hydrophobic domain, E. histolytica thioredoxin-thioredoxin
reductase system was primarily located in the plasma membrane
(Arias et al., 2008) without evidence of intracytoplasmic presence.
Besides ROS, E. histolytica is exposed to high concentrations
of reactive nitrogen species (RNS) such as nitric oxide (NO)
or S-nitrosothiols (such as GSNO and CySNO) during tissue
invasion. Although high levels of these RNS might inhibit E.
histolytica growth in vitro (Arias et al., 2012), the parasite is able
to survive and multiply during tissue invasion. This suggests that
E. histolytica detoxification system is versatile enough to tolerate
hostile environments. This versatility was recently demonstrated
by E. histolytica Trx-TrxR system ability to reduce RNS and use
an alternative electron donor such as NADH (Arias et al., 2012).
As E. histolytica lacks glutathione, Cys is its major intracellular
low molecular mass thiol (Nozaki et al., 1999) that can also react
with NO to generate CysSNO. This metabolite is considered
critical for S-nitrosylation (addition of NO to the thiol group in
Cys) or S-thiolation (addition of Cys to another Cys thiol group)
of cellular proteins (Arias et al., 2012). These metabolites can be
reduced by EhTrxR as was demonstrated by in vitro assays where
NADPH and EhTrxR were exposed to different concentrations
of CySNO and GSNO. The rates of NADPH oxidation were
increased proportionally, suggesting that these compounds
(CySNO or GSNO) can be reduced in a reaction catalyzed by
EhTrxR. The EhTrxR/Trx system reduces S-nitrosothiols (Arias
et al., 2012) compounds and metronidazole (Leitsch et al., 2007)
as well as interacts with downstream peroxidases that are critical
for cellular redox homeostasis (Schlosser et al., 2013).
Unlike other thioredoxin reductases, EhTrxR does not exhibit
high specificity for NADPH. Arias et al. (2012) evaluated the
reduction of DTNB by EhTrxR using NADPH or NADH as
electron donors. Although EhTrxR affinity for NADH is 10 times
lower than that for NADPH, the enzyme activity with NADH is
not negligible when compared to other thioredoxin reductases
that exhibit high specificity toward NADPH (Arias et al., 2012).
These results suggest that EhTrxR can use either NADPH or
NADH as its reduced co-factor. This evidence strongly shows
the versatility of EhTrx and its ability to protect the parasite
from the ROS and RNI byproducts during host invasion.
Altogether, EhTrxR properties make it an ideal drug target.
In fact, metronidazole decreases EhTrxR reductase activity, by
forming covalent adducts with this enzyme.
Giardia lamblia Thioredoxin Reductase
Giardia lamblia (synonyms: G. intestinalis or G. duodenalis) is
a flagellate whose trophozoites live in the small intestine, while
the infectious cysts are shed in feces and survive outside the
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host. Giardia cysts can infect or re-infect humans, and can be
transmitted in food, water or fomites since they are resistant to
environmental conditions and chemicals. Giardia is considered
an aerotolerant organism as even its cyst is able to take up oxygen,
although only at 10–20% of the level of trophozoites (Paget et al.,
1993).
G. lamblia has a genome size of approximately 10–12 Mb
divided among five chromosomes (Adam, 2001). Giardia isolates
are divided into eight assemblages (genotypes) from A to H.
Assemblages A and B are the only ones typically associated
with human infections (Adam, 2001). Both human Giardia
assemblages A and B possess a single TrxR-encoding gene (GL
50803_9827 and GL50581_832). This single gene is 945 bp in
length, lacks introns and encodes a 314 amino acid protein
(GLTrxR) with a molecular mass of approximately 33.8 kDa and
a pI of 6.59.
Like most aerotolerant protozoans, G. lamblia lacks
mitochondria, superoxide dismutase, catalase, glutathione-
glutathione reductase system but possesses a thioredoxin-
thioredoxin reductase system while cysteine is its major low
molecular weight thiol (Brown et al., 1998). Given the lack
of ROS-dependent anti-oxidant systems and glutathione,
the thioredoxin-thioredoxin reductase system is thought to
constitute a major part of the antioxidant defense in this
organism. It consists of a soluble dimeric FAD containing
NADPH-dependent disulfide reductase, which contains a
two 35-kDa subunits and a partially purified 12-kDa protein;
a putative thioredoxin, a low molecular weight thioredoxin
reductase (TrxR), which has 75% identity to the E. coli
thioredoxin reductase (Brown et al., 1998), and a thioredoxin-
peroxidase. All genes are expressed in trophozoites and cysts,
although transcripts of most genes are present at lower levels
in cysts (Faghiri and Widmer, 2011). Since Giardia cysts can
take up oxygen (Paget et al., 1993), the Giardia thioredoxin-
thioredoxin reductase systemmust also be important to maintain
oxidation/reduction homeostasis in its trophozoites and cyst
forms, making it an attractive drug target. This target is even
more important given that metronidazole, a drug used in the
treatment of giardiasis, had no detectable effect on oxygen uptake
or viability in cysts due to impermeability of the Giardia cysts to
metronidazole (Paget et al., 1993).
Thioredoxin Reductase-gold Interactions: An
Unexploited Drug Target
Despite the huge public health burden of parasites worldwide, the
paucity of available anti-parasitic drugs is striking. Reprofiling of
old FDA approved drugs has become an alternative expeditious
approach to drug discovery. Its advantage relies on already
known drug safety and pharmacokinetic effects in humans that
make them readily available for off-label indications.
Auranofin, originally approved to treat rheumatoid arthritis,
is now the leading compound for anti-parasitic treatment
development. Indeed, we have recently demonstrated that
auranofin has activity against trophozoites of Entamoeba
histolytica (Debnath et al., 2012) and Giardia lamblia (Tejman-
Yarden et al., 2013). Due to its activity shown in high throughput
screening studies, in vitro and in vivo rodent models of
colitis and liver abscesses, auranofin was granted Orphan Drug
Status. Auranofin has also shown promising activity against
metronidazole-resistant Giardia lamblia (Tejman-Yarden et al.,
2013), Plasmodium falciparum (Sannella et al., 2008), Schistosoma
mansoni (Angelucci et al., 2009), Leishmania infantum (Ilari
et al., 2012), Brugia malayi and Onchocerca (Bulman et al., 2015).
Thus, auranofin has the potential to become an alternative broad
spectrum anti-parasitic agent.
Auranofin as an Anti-parasitic Agent
Auranofin was the first oral gold salt approved by the FDA to
treat rheumatoid arthritis over 25 years ago. Its pharmacokinetic
characteristics are distinct from those of gold sodium thiomalate,
a chrysotherapy agent of systemic administration. (Blodgett,
1983; Blodgett et al., 1984). Despite its clinical use, auranofin’s
mechanism of action is poorly understood.
Kuntz et al. (2007) were the first ones to describe the effect
of auranofin in S. mansoni. In in vitro assays, they demonstrated
FIGURE 1 | (A) In vitro susceptibility of trophozoites (control and treated with
auranofin) to reactive oxygen species (H2O2) and the effect of added cysteine.
Time points with mean ± SEM % survival. Experiments are shown in
triplicates. *p < 0.002 by Student’s t-test. (B) Immunoflouroscence
microscopy: Detection of reactive oxygen species within E. histolytica
trophozoites following treatment with auranofin or auranofin plus H2O2.
Control trophozoites were treated with ethanol alone (auranofin carrier). Insets
are differential interference contrast images. Scale bars, 10µm. Figures were
first published in Andrade and Reed (2015).
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FIGURE 2 | Experimental mice model of amebic colitis. Control and
treatment with auranofin groups (n = 8) are presented as: (A) The percentage
of trophozoites per gram of tissue. (B) Or myeloperoxidase (MPO) units per
gram of tissue compared with the means of infected controls (as 100%).
that auranofin rapidly killed juvenile and adult forms of S.
mansoni (Kuntz et al., 2007). Their preliminary in vivo data
correlated with their in vitro findings: mice infected with S.
mansoni and treated with auranofin showed a 59 and 63%
decrease in worm burden compared to control mice.
Additionally, auranofin strongly inhibits the growth of
malarial parasite Plasmodium falciparum (Sannella et al., 2008),
the pro-mastigote stage of Leishmania infantum (Ilari et al.,
2012), the bloodstream and procyclic stages of Trypanosoma
brucei (Lobanov et al., 2006) and the larval worms of
Echinococcus granulosus (Bonilla et al., 2008). In all these
studies, auranofin’s anti-parasitic dose was in in the nanomolar
range, which is achievable in patients with rheumatoid arthritis
(approximately 5µM serum blood levels) (Debnath et al., 2012).
Angelucci et al. further analyzed S. mansoni thioredoxin-
glutathione reductase (TGR) crystal structure in the presence
of auranofin (Angelucci et al., 2009). The structure revealed
gold (I) rather than auranofin as an adduct between pairs of
cysteines (Cys-Au-Cys) in two different sites and also bound to
the proposed NADPH binding site of the reductase in a third
location.
Similarly, the crystal structure of reduced Leishmania
infantum trypanothione reductase complexed with NADPH and
auranofin also demonstrated that gold binds two active cysteine
residues of trypanothione reductase (TryR) (Ilari et al., 2012),
i.e., Cys52 and Cys57, while the thiol sugar moiety of auranofin
binds to the trypanothione binding site; thus auranofin appears
to inhibit TryR through a dual mechanism.
We recently demonstrated that auranofin has activity
against E. histolytica trophozoites (Debnath et al., 2012).
Our studies support the hypothesis that EhTrxR likely is the
target for auranofin. Our qualitative in vitro assays showed
that E. histolytica trophozoites treated with auranofin were
more susceptible to oxidative stress in a time dependent
manner (Figure 1A). Staining E. histolytica trophozoites with
dichloro-dihydrofluorescein, which fluoresces green upon
contact with ROS, showed that trophozoites treated with
auranofin accumulated more ROS (Debnath et al., 2012)
(Figure 1B). This effect was inhibited by cysteine, the major
reductant in E. histolytica, which protected trophozoites that
were treated with auranofin (Figure 1). Our in vitro findings
were corroborated in animal models of colitis and liver abscesses
where auranofin not only decreased the parasite tissue burden,
but also the local inflammatory response as measured by
activity of myeloperoxidase in cecal tissue (Debnath et al.,
2012) (Figures 2A,B respectively). Besides its activity against
trophozoites, auranofin seems to have activity against cysts of E.
invadens, the only ameba to readily encyst in vitro (R. Andrade,
manuscript in preparation).
G. lamblia assemblages A and B were also susceptible to
auranofin, as demonstrated by Tejman-Yarden et al. (2013).
Auranofin displayed a half-maximal effective concentrations
(EC50s) of 4–6µM at 48-h. Most importantly, auranofin was
able to overcome resistance to metronidazole. In fact, the
EC50 for auranofin was not significantly different between
metronidazole- sensitive parental Giardia isolates and several of
their metronidazole-resistant isogenic derivative lines.
Similarly, to E. histolytica andG. lamblia, auranofin was found
effective against C. parvum in vitro with EC50 about 2µM,
whichwas comparable to nitazoxanide, the current drug of choice
(Debnath et al., 2013).
Altogether, these findings suggest that auranofin may be a
new promising broad spectrum antiparasitic agent with activity
against ameba, giardia and cryptosporidium. Currently, clinical
trials using auranofin to treat ameba and giardia infections are
about to begin.
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